Ramipril cost effective in patients at high risk for cardiovascular events

By  

Inpharma, Vol. 1, Iss. 1460, 2004-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Ramipril in Patients at High Risk for Cardiovascular Events: Economic Evaluation of the HOPE (Heart Outcomes Prevention Evaluation) Study for Germany from the Statutory Health Insurance Perspective

By Peter K. Schädlich  

PharmacoEconomics, Vol. 22, Iss. 15, 2004-01 ,pp. : 955-973

Adis International

Access to resources Recommend Favorite

Ramipril: A Review of its Use in Preventing Cardiovascular Outcomes in High-Risk Patients

By Anderson Vanessa R.   Perry Caroline M.   Robinson Dean M.  

American Journal of Cardiovascular Drugs, Vol. 6, Iss. 6, 2006-01 ,pp. : 417-432

Adis International

Access to resources Recommend Favorite

Tolerability of Ramipril 10 mg/day in High-Risk Cardiovascular Chinese Patients

By Wu N.   Zhu J.R.   Chen K.A.  

Clinical Drug Investigation, Vol. 22, Iss. 11, 2002-01 ,pp. : 771-781

Adis International

Access to resources Recommend Favorite

Abciximab for high-risk patients: effective at a cost

By  

Inpharma, Vol. 1, Iss. 1262, 2000-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite